The article reviews strategies for firms with or without existing in-house capacities and the pros and cons for outsourcing bio/pharmaceutical development and manufacturing.
Oskar Gold
Advertisement
Oskar Gold is Vice President, Key Account Management & Corporate Marketing, at Vetter.
Articles by Oskar Gold
Advertisement
Latest Updated Articles
Insourcing vs Outsourcing: Choosing the Right StrategyPublished: May 15th 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
5
